Research chemicalResearch chemicalPsychedelicTryptamine

4-AcO-MiPT

Also known as 4-acetoxy-MiPT · 4-AcO-MiPT

Written by enwyReviewed 4 Aug 20262 sources0 comments

4-AcO-MiPT (4-acetoxy-N-methyl-N-isopropyltryptamine) is a synthetic tryptamine and presumed prodrug of 4-HO-MiPT. It is used non-medically as a psychedelic. Human evidence is anecdotal only; potency, pharmacokinetics and safety are uncharacterised, with wide individual variation in dose response.

01 Overview

4-AcO-MiPT is the acetate ester of 4-HO-MiPT and is presumed to be deacetylated in the body to the active psilocin-analogue. User reports describe a bright, visually rich psychedelic experience comparable to 4-HO-MiPT.

There are no controlled human data; effect and dose information come from self-experimentation and harm-reduction reports. As a research chemical of uncertain purity, dose responses vary widely, and challenging psychological reactions can occur, particularly at higher doses.

02 Mechanism

Presumed prodrug hydrolysed to 4-HO-MiPT, a serotonin 5-HT2A receptor agonist (classical psychedelic mechanism).

03 Dosing

Tier	Dose	Route	Notes
Threshold	5–10 mg	Oral	Approximate; assumed similar to 4-HO-MiPT.
Common	15–25 mg	Oral	Onset ~30-60 min, duration ~4-6 h. Not clinically validated.
Strong	25–35 mg	Oral	Overwhelming effects more likely.

04 Effects

Effect	Magnitude	Evidence
Visual effectsOpen- and closed-eye visuals and colour enhancement reported.		Anecdotal
Stimulation and euphoriaEnergetic, mood-lifting quality reported, similar to 4-HO-MiPT.		Anecdotal
Altered perceptionChanges in cognition and time perception typical of psychedelics.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Stimulation / insomniaRestlessness and disrupted sleep reflecting stimulating character.	Mild	Common	Anecdotal
Cardiovascular stimulationIncreased heart rate and blood pressure.	Mild	Common	Anecdotal
Anxiety / challenging experienceAnxiety or panic, more likely at high doses or in unfavourable setting.	Moderate	Common at higher doses	Anecdotal

06 Legal status

United Kingdom

Class A / tryptamine controls

Covered by UK tryptamine provisions. · as of Jan 2026

United States

Not federally scheduled by name; possible Federal Analogue Act exposure. · as of Jan 2026

07 References

TiHKAL: The Continuation (4-HO-MiPT entry)Shulgin & Shulgin, 1997

New psychoactive substances monitoringEUDA (formerly EMCDDA)

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.